The use of genomic analysis to evaluate mesothelioma causation is a topic that will be covered at the upcoming Perrin Conference on Cutting-Edge Issues in Asbestos Litigation. As part of a panel, ToxicoGenomica’s Kirk Hartley will discuss several topics at the intersections between genomic science and law. One portion of his talk will focus on […]
As we have written over the past few years, expert testimony involving genetic findings is becoming more and more common in asbestos litigation. As we wrote previously, on Wednesday, July 17 (2019) Dr. Len van Zyl of ToxicoGenomica presented at the Perrin Mid-Atlantic Asbestos Conference where he discussed important new emerging science relevant to the […]
Genomics is a proven and reliable quantitative tool that has dramatically improved cancer treatment, established the practice of personalized medicine, and brought binary clarity to paternity and criminal cases. Genomics is now transforming how civil toxic tort cases are adjudicated. We have hit a tipping point where, instead of merely relying on population-based epidemiological studies, […]
As the application of genomic sciences becomes common in toxic tort litigation, savvy litigators are occasionally concerned about whether genomic information may backfire on the defense or the plaintiff. For example, defense lawyers may worry that plaintiff’s counsel may argue that an exposure to a minute amount of a toxicant caused an injury through an […]
As the application of genomic science becomes more common in toxic tort litigation, savvy litigators are thinking about how statements about genetic findings may fit into legal categories or terms of art. In our view, non-scientists need to keep in mind that words used as terms of art for genetic findings are not necessarily equivalent […]
Each year, adverse drug events cost millions of dollars in hospital admissions, injuries to patients, and malpractice. And companies spend billions of dollars on litigation involving allegations that their drugs caused adverse drug reactions (ADRs). What if there was a better way to determine individualized drug adverse events? Welcome to the Age of Proteomics The […]
To avoid needless ethical and/or legal disputes and to avoid wasting time and money, it’s important to think about genomic issues early on in a case. It’s also useful to look across sets of cases to get a clearer understanding of how genomics can provide an effective strategy. In general, it’s desirable and cost-effective to […]